Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Insight Molecular Diagnostics Inc. Director's Dealing 2020

Aug 31, 2020

34238_dirs_2020-08-31_bea679d5-7b29-4584-b6b6-7eb2440e5cf3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2020-08-24

Reporting Person: Carter Jennifer L. (Director)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Option to Purchase Common Stock $1.40 2030-08-23 Common Stock (57000) Direct